Bajaj FInserv Healthcare Fund - Regular - Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 27-12-2024
AUM:
376.77 Cr
Expense Ratio
2.56%
Benchmark
BSE Healthcare TRI
ISIN
INF0QA701987
Minimum Investment
500.0
Minimum Topup
100.0
Minimum SIP Amount
500
Fund Manager
Mr. Nimesh Chandan, Mr. Sorbh Gupta, Mr. Siddharth Chaudhary
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Bajaj FInserv Healthcare Fund - Regular - Growth | 19.42 | - | - |
| Benchmark | - | - | - |
If you invested in this fund:
₹
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
11.652
Last change
-0.09 (-0.7552%)
Fund Size (AUM)
₹ 376.77 Cr
Performance
9.35% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. However, there is no assurance that the investment objective of the Scheme will be achieved.
Fund Manager
Mr. Nimesh Chandan, Mr. Sorbh Gupta, Mr. Siddharth Chaudhary
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 8.4 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 6.71 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 6.52 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 6.36 |
| PIRAMAL PHARMA LIMITED EQ | 6.04 |
| Rubicon Research Ltd. | 6.02 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 5.26 |
| NEULAND LABORATORIES LIMITED EQ | 4.59 |
| EMCURE PHARMACEUTICALS LIMITED EQ | 4.36 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 4.16 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 85.59 |
| Fast Moving Consumer Goods | 2.82 |
| Capital Goods | 2.35 |
| Chemicals | 2.17 |
| Financial Services | 2.04 |
| Consumer Services | 1.18 |